Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics, Inc. - Common Stock (NQ:DRMA)

2.260 +0.060 (+2.73%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dermata Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
News headline image
Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase
Via ACCESSWIRE
News headline image
Why Hill International Shares Are Trading Higher By 58%: Here Are 25 Stocks Moving Premarket ↗
Gainers Hill International, Inc. (NYSE: HIL) shares rose 58.1% to $2.75 in pre-market trading after the company agreed to be acquired by Global Infrastructure Solutions Inc. for $2.85 per share. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
  
Via Benzinga
News headline image
Dermata Therapeutics: Q2 Earnings Insights ↗
  Dermata Therapeutics (NASDAQ:DRMA) reported its Q2 earnings results on Monday, August 15, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Conformis (NASDAQ:CFMS) shares moved upwards by 13.2% to $0.29 during Monday's after-market session. The company's market cap stands at $53.5 million. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
  
Via Benzinga
News headline image
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday ↗
Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Tesla, Twitter And 76 Biggest Movers From Friday ↗
Gainers Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board... 
Via Benzinga
News headline image
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday. 
Via Benzinga
News headline image
This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday ↗
Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday ↗
Gainers Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64. Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Good morning, trader! It's time for another look at the biggest pre-market stock movers as we dive into the latest news for Friday! 
Via InvestorPlace
News headline image
Akebia Therapeutics And 20 Stocks Moving Premarket ↗
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 83.2% to $0.8250 in pre-market trading after dropping 10% on Thursday. 
Via Benzinga
News headline image
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday ↗
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical... 
Via Benzinga
News headline image
Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea
- Topline results expected in the second half of 2022 - 
From Dermata Therapeutics
Via AccessWire
News headline image
Dermata to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, CA / ACCESSWIRE / May 23, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and... 
From Dermata Therapeutics
Via AccessWire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Dermata completes a $5.0 million private placement financing DMT310 Phase 2 rosacea trial topline results expected in H2 2022 SAN DIEGO, CA / ACCESSWIRE / May 16, 2022 / Dermata Therapeutics, Inc.... 
From Dermata Therapeutics
Via AccessWire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / April 25, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of... 
From Dermata Therapeutics
Via AccessWire
News headline image
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / April 21, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment... 
From Dermata Therapeutics
Via AccessWire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results
DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022 DMT310 Phase 2 psoriasis trial to start H1 2022, with topline results expected in H1 2023 DMT310 Phase... 
From Dermata Therapeutics
Via AccessWire
News headline image
Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference
SAN DIEGO, CA / ACCESSWIRE / March 24, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and... 
From Dermata Therapeutics
Via AccessWire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Palisade Bio (NASDAQ:PALI) shares rose 34.1% to $1.08 during Tuesday's regular session. Trading volume for this security as of 13:31 EST is 52.4 million, which... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.